Skip to main content
Premium Trial:

Request an Annual Quote

CLC Bio, Ingenuity Systems Integrate Technologies

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – CLC Bio and Ingenuity Systems today announced that they are integrating certain software products for life science research.

The firms said that they will collaborate to provide interoperability between CLC Bio's enterprise and desktop solutions and Ingenuity Systems' pathway analysis software to provide researchers with array and next-generation sequencing data and knowledge analyses.

"The costs of sequencing full genomes are now at a price level where we see a lot of industries and research areas moving into high-throughput sequencing in order to benefit from the added scientific value these new technologies can provide," CLC Bio Director of Consulting Solutions Jannick Bendtsen said in a statement. "The interoperability of Ingenuity's IPA with CLC Genomics Server and CLC Genomics Workbench is a solution that will provide an efficient workflow experience for scientists working with large next-generation sequencing datasets, directly from high-performance analyses to biomarker discovery and research diagnostic development."

Financial and other terms of the alliance were not disclosed.

The Scan

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.

Study Reveals Potential Sex-Specific Role for Noncoding RNA in Depression

A long, noncoding RNA called FEDORA appears to be a sex-specific regulator of major depressive disorder, affecting more women, researchers report in Science Advances.

New mRNA Vaccines Offer Hope for Fighting Malaria

A George Washington University-led team has developed mRNA vaccines for malaria that appear to provide protection in mice, as they report in NPJ Vaccines.

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.